…big pharma… psychedelics
…the increasing interest that mainstream biotech firms are developing for psychedelic compounds.
While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, Big Pharma has largely taken a back seat in the growing industry, holding off on conducting trials or acquiring companies working with the compounds.
Original Article (Business Insider):
Compass Pathways’ new CEO says data from his firm’s upcoming clinical trial could finally persuade Big Pharma to jump into the psychedelics industry
Artwork Fair Use: Molino J, Lubiana Alves T, Ferreira-Camargo L, Croce M, Tanaka A, Buson F, Ribeiro P, Campos-Salazar A, Antonio E, Maizel A, Siratuti V, Costa C, Wlodarczyk S, de Souza Lima R, Mello F, Mayfield S, Carvalho J
